What is your approach to patients who experience widespread progression on EGFR inhibitors found to have MET amplification on tumor biopsy in addition to sensitizing EGFR mutation?
Community PollStarted
How would you treat metastatic NSCLC patient with EGFR exon 19 deletion and MET amplification who has progression on osimertinib not amenable to local therapy?
75 physicians have voted
Join Mednetto vote and see how they answered.
2 Answers
Mednet Member
Medical Oncology · Yuma Regional Medical Center Cancer Center
Answered on
Ideally, speaking they should be enrolled in clinical trials with a bispecific antibody for EGFR and CMET or drugs targeting CMET with continued EGFRi. There is a paucity of data on continuing Osimertinib on progression with Crizotinib or Capamatinib. In clinical practice, chemo or chemoIO is also a...
Join for free or sign in to see the full answer
Mednet Member
Medical Oncology · Cancer Care Specialists/Renown Oncology/UNR
Answered on
Amivantamab off label once it is approved in Exon 20 mutation. Combination with Lazertinib is safe per CHRYSALIS, but the current trial appears to be in the frontline.
Join for free or sign in to see the full answer